The European Commission has approved Celltrion Healthcare’s rituximab biosimilar – Truxima (CT-P10) – for the same autoimmune disease and cancer indications as the reference product.
Celyad SA has enrolled the first multiple myeloma patient in a safety and tolerability trial of its CAR-T therapy.
Vaccines do not cause autism and people who say otherwise are wrong.
Cambridge Research Biochemicals (CRB) has launched a second catalogue of research antibodies for academia, pharma and outsourcing firms.
Sanofi has contracted Swiss biotech Selexis SA to develop cell lines for a three early stage projects.
CellGenix GmbH has started expanding its cell and gene therapy reagents facility in Freiburg, Germany citing the progression of customer projects into clinical development and commercial launch.